1
-
3
of
3
results (0.48 seconds)
Sort By:
-
Session 108: Outcome Based Risk Sharing Arrangements – From Theory to Practice
and pharmaceutical manufacturers (“pharma”), and it’s intended to meet the needs of actuaries who focus ... background of OBRSAs, definitions, stakeholders, and OBRSA’s role in shifting the system from volume-based toward ...- Authors: Karl J. Gregor, Whitney Pratt, Jim Xun Jun Li
- Date: May 2019
- Competency: External Forces & Industry Knowledge
- Topics: Health & Disability>Health risks; Technology & Applications>Analytics and informatics
-
Session 133: Leveraging Real-World Data to Enhance Existing Actuarial Analytics and to Potentially Evolve Actuarial Methods and Value Drivers
the product lifecycle H EO R d el iv er ab le s • Patient experience endpoint identification, development ... • Input to trial design in terms of comparator(s) • Input to trial recruitment • Validation of PCO ...- Authors: James Dolstad, Karl J. Gregor, Andrew Mackenzie, David L. Van Brunt
- Date: May 2019
- Competency: External Forces & Industry Knowledge
- Topics: Economics>Health economics; Health & Disability>Health insurance
-
Session 015: Actuaries and Pharmaceutical Manufacturers: Friend or Foe?
Indication(s) being sought Burden of illness Clinical study protocol(s) Dosing/use regimen Endpoint(s) being ... development Pharma Constraints & Considerations U.S. Department of Health and Human Services, Food and ...- Authors: Whitney Pratt, Jason Fehr, Karl J. Gregor
- Date: May 2019
- Competency: Strategic Insight and Integration
- Topics: Actuarial Profession>Professional development; Economics>Health economics